论文部分内容阅读
目的:探讨美托洛尔治疗陈旧性心肌梗死合并慢性心力衰竭的疗效和安全性。方法:陈旧性心肌梗死合并慢性心力衰竭患者80例,随机分为治疗组与对照组各40例,治疗组给予美托洛尔治疗,对照组给予阿替洛尔治疗。2周后评价两组疗效和安全性。结果:治疗组有效率为95.0%,高于对照组的有效率75.0%(P<0.05)。在用药后第10 min、60 min,治疗组心率较对照组下降更显著(P<0.05)。两组死亡率、再次入院率比较,差异无统计学意义(P>0.05)。两组均未发生药品不良反应。结论:相对于阿替洛尔,美托洛尔治疗陈旧性心肌梗死合并慢性心力衰竭能有效提高治疗疗效,降低心率,安全性好,值得推广应用。
Objective: To investigate the efficacy and safety of metoprolol in the treatment of chronic myocardial infarction complicated with chronic heart failure. Methods: Eighty elderly patients with chronic myocardial infarction and chronic heart failure were randomly divided into treatment group and control group, 40 cases each. Metoprolol was given to the treatment group and atenolol was given to the control group. Two weeks later, the efficacy and safety of two groups were evaluated. Results: The effective rate was 95.0% in the treatment group and 75.0% in the control group (P <0.05). At 10 min and 60 min after treatment, the heart rate of the treatment group decreased more significantly than that of the control group (P <0.05). There was no significant difference in mortality and re-admission rate between the two groups (P> 0.05). No adverse drug reactions occurred in both groups. Conclusion: Compared with atenolol, metoprolol treatment of old myocardial infarction with chronic heart failure can effectively improve the therapeutic efficacy, reduce heart rate, good safety and should be popularized and applied.